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Lisofylline, 1-(5-R-hydroxyhexyl)-3,5-dimethyl-
xanthine (LSF) (Figure 1) is a novel, modified
methylxanthine with anti-inflammatory properties.
It was originally developed to reduce cellular dam-
age due to ischemic reperfusion, hypoxia or autoim-
mune diseases (1, 2). Only the R stereoisomer is bio-
logically active. LSF is several hundred-fold more
effective than its parent compound, pentoxifylline
(PTX), at inhibiting responses to the release of
inflammatory cytokines (2). LSF inhibits stress-
activated lipid metabolism and suppresses the pro-
duction of inflammatory cytokines, such as inter-
leukin 12 (IL-12) (3), which exert these effects
through a common lipid intracellular signalling
pathway. It also reduces toxicity and improves
patient response to cancer chemotherapy and radia-
tion therapy (4, 5). LSF can decrease the dysfunc-
tion caused by IL-1β in pancreatic islets, which indi-
cates possible therapeutic value in the prevention of
autoimmune disorders, including type I diabetes, in
autoimmune recurrence following islet transplanta-
tion, and in the preservation of β cell functional
mass during isolation (6-8).
LSF can be synthesized in several different
ways, using chemical multiple-step methods (9, 10)
or a microbial procedure with Rhodotula rubra (11).
As LSF is not commercially available in our coun-
try we had to produce it for pharmacokinetic studies.
A new, simple method was developed based on the
enantioselective reduction of 1-(5-oxohexyl)-3,7-
dimethylxanthine (PTX) using bakerís and wine
yeasts as biocatalysts (Figure 2). Among numerous
enzymes in yeast (Saccharomyces cerevisiae) alco-
hol dehydrogenases (YADH) play an important role
in the oxidation and reduction of hydroxyl or car-
bonyl functions in aldehydes, ketones, keto esters
and keto acids (12-17). YADH has very narrow sub-
strate specificity and generally accepts only aldehy-
des and methyl ketones (18, 19). Thus, YADH is of
limited use in the preparation of chiral secondary
alcohols (which include LSF). YADHs are ubiqui-
tous enzymes involved in many physiological
processes: they contain four Zn(II) atoms near the
active site (20). Alcohol dehydrogenases may be
employed as purified crude enzymes or as compo-
nents of whole cells. The fundamental difference
between the use of isolated enzymes and whole cells
is that in the former case the cofactors necessary for
the regeneration of the NAD(P)/NAD(P)H must be
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necessary enzymes to achieve cofactor recycling.
The disadvantage of using whole cells is that they
frequently contain more than one oxidoreductase
and the activity displayed depends on a number of
factors including the structure of the substrate and
the metabolic state of the cell. Nevertheless, proce-
dures using whole microorganisms, for example
Saccharomyces cerevisiae, are simple and inexpen-
sive. In addition, their use does not require sterile
fermentors and therefore they can be handled using
standard laboratory equipment.
This study presents the results of the stereose-
lective reduction of PTX into LSF when catalyzed
by whole cells of bakerís yeast and a few strains of
wine yeast, in both water and organic solvents. The
enantiopure LSF was examined using the HPLC
method with a chiral stationary phase.
EXPERIMENTAL
Materials
Pentoxifylline was obtained from Polpharma
S.A., Poland; n-hexane and 2-propanol of HPLC
grade were purchased from Merck, Darmstadt,
Germany. The other reagents were all of analytical
grade. Microorganisms: five strains of Saccharo-
myces cerevisiae: KKP13, KKP35, KKP82,
KKP295, KKPU were obtained from the Collection
of Productive Microorganisms, Department of
Technical Microbiology and Biochemistry in
Warsaw, Poland; another two strains, Líhirondelle
and Asmussen, were obtained from Lesaffre
Biocorporation, France and Oetker Nahrungsmittel
K. G., Germany, respectively.
Methods of analysis
High performance liquid chromatography 
The identification of starting materials and
reduction products, each yields of transformation
and enantiomeric excess, were determined by HPLC
analysis on a Daicel Chiralpak AD column. The
high-performance liquid chromatograph (Dionex
Corporation, USA) consisted of an isocratic solvent
delivery system (Dionex HPLC Pump Series P580),
an injector equipped with a 20 µL loop and a vari-
able wavelength UV detector (model Dionex
UV/VIS detector UVD 170S/340S) set at 275 nm.
The analytical chiral column was 250 mm x 0.46 cm
i.d. Daicel Chiralpak AD (Chemical Industries,
France). The temperature was set at 25OC. The
mobile phase was n-hexane: 2-propanol 780:220 per
1L phase, vacuum-degassed before use and the flow
rate was 1 mL min-1. The analytes were dissolved in
2-propanol (at a concentration of 1mg/mL).
Chromatographic characteristics
All chromatographic data are presented in
Table 2.
The separation factor (α) was expressed as
α = k2 / k1 (1)
where k1, k2, are the retention factors for the first and
second eluting enantiomer, respectively. The reten-
tion factors k1 and k2 were calculated as follows:
k1 = (tR1 ñ t0) / t0 and k2 = (tR2 ñ t0) / t0 (2)
where t0, tR1 and tR2 are the dead elution time of enan-
tiomers.
The resolution (Rs) of the first and second elut-
ing enantiomers was calculated from the ratio of the
difference between the elution times tR1 and tR2 to the
arithmetic mean of the two peak widths w1 and w2.
Rs = 2(tR2 ñ tR1) / (w1 + w2) (3)
The difference in the free energy (-∆(∆GO))
was calculated from the separation factor according
to the following equation:
Figure1. Chemical structure of lisofylline.
Figure 2. Reduction pathway of pentoxifylline.
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-∆(∆GO) =RT ln α (4)
Polarimetry 
The measurements of the optical rotation prod-
ucts of the stereoselective reduction of PTX were
carried out on a Digital Polarimeter ñ DIP 2000
(Jasco Inc., Japan). The optical rotation R and S-1-
(5-hydroxyhexyl)-3,5-dimethylxanthine were in
agreement with the literature values (9,11) {for R
enantiomer [α]D20 -5.6o (c=6.7, EtOH); for S enan-
tiomer [α]D20 5.6o (c=6.7, EtOH)}.
Spectroscopy 
1H NMR spectra for the racemic standard and
each enantiomer were recorded with a Varian VM
300 Hz instrument using tetramethylsilane (TMS) as
the internal standard. The IR spectra were recorded
in KBr pellets on Jasco Spectrometer FT/IR-410.
Chemical synthesis 
1-(5-R,S-hydroxyhexyl)-3,5-dimethylxanthine
(HOPTX) ñ racemic standard
HOPTX was synthesized from PTX using
sodium borohydride reduction. Briefly, 140 mg (0.5
mmol) of PTX was dissolved in 10 mL of methanol
and 160 mg (2.5 mmol) of sodium borohydride was
added. The mixture was stirred overnight at room
temperature. The progress of the reaction was con-
firmed by thin layer chromatography (benzene : ace-
tone 1:1, v/v). After solvent evaporation the reaction
product was extracted with methylene chloride. The
organic layer was washed three times with saturated
sodium chloride solution and concentrated under
reduced pressure. The residue was recrystallized
from ethyl ether. M.p. 109-1110C; 92% yield;
HPLC: tr = 27.50; 32.00 min; IR (KBr) cm ñ1: 3374
(OH), 1698 (CO), 1654 (CO); 1H NMR 300 MHz
[DMSOd6]: d [ppm]: 1.00 (d, J = 6.0 Hz, 3H, CH3-
CH), 1.26 (m, 4H, CH2-CH2), 1.46 (m, 2H, CH2-
CHOH), 3.40 (s, 3H, N-CH3), 3.53 (m, 1H, CH),
3.80 (t, J = 7.4 Hz, 2H, N-CH2), 3.85 (s, 3H, N-CH3),
4.30 (s, 1H, OH), 7.97 (s, 1H, Im-H)
Microbiological methods
Biotransformation of PTX in an aqueous medium
In a typical experiment 2 g of wine yeast
(KKP) or 5 g of bakerís yeast was suspended in of
150 mL phosphate buffer. After stirring for 30 min
at 30oC, 5 g of glucose and 117 mg (0.5 mmol) of
PTX were added. After stirring for 5 days at 30oC
the yeasts were filtered off. The filtrate was extract-
ed three times with 100 mL methylene chloride and
dried over Na2SO4. The residues obtained from the
evaporation of the solvent were dissolved in 2 mL of
2-propanol for HPLC analysis or purified by silica
gel chromatography.
Table 1. Bioconversion of PTX in water and in organic solvents
Strains Yields in water Yields in AcOEt Yields in hexane Yields in toluene
[%] ee[%] [%] ee[%] [%] ee[%] [%] ee[%]
KKP13 57 37 (R) 1 60 (S) ndb 1 82 (S)
KKP35 90 85 (R) óóó-a 25 43 (R) 1 98 (S)
KKP82 48 51 (R) 1 58 (S) óóó- 1 99 (R)
KKP295 65 43 (R) 1 32 (S) nd 1 100 (R)
KKPU 95 98 (R) 1 68 (S) óóó- 2 40 (S)
Líhirondelle 45 64 (S) nd nd nd
Asmussen 68 94 (S) nd nd nd
a) óó: biotransformation not observed; 
b) nd: not determined
Table 2. Chromatographic data 
Mean values
with:
k1 α Rs -∆(∆G
O) (J . mol-1) 
SD 6.95 ±0.16 1.171 ± 0.009 2.397 ±0.272 391.4 ±17.7
SEM 6.95 ± 0.06 1.171 ± 0.003 2.397 ± 0.103 391.4 ± 7.5
(k1) retention factors; (α) separation factors; (Rs) resolution; (-∆(∆G
o)) difference in free energies for enantiomeric separa-
tion. The chromatographic conditions: n-hexane/2-propanol 780/220 (v/v); flow rate 1.0 mL/min; column temperature 25OC;
UV detection at 275 nm; injection 20 µL. 
Mean values for chromatographic data with SD and SEM were determined on the base of results from seven experiments.
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Biotransformation of PTX in organic media 
1 g of dry bakerís or wine yeast was suspended
in 25 mL of the organic solvent and 2 mL of tridis-
tilled water was added. After the addition of 58 mg
(0.25 mmol) of PTX the suspension was stirred for
3 days at 27oC. The yeast was then filtered off, the
solution concentrated in vacuo, and the residue was




was reduced with NaBH4 to the racemic standard ñ
R,S-1-(5-hydroxyhexyl)-3,5-dimethylxanthine
(HOPTX) ñ which was used as the reference agent
in the further analytical research.
The aim of this study was to find a strain of
Saccharomyces cerevisiae yielding enantiomerically
pure (R-1-(5-hydroxyhexyl)-3,5-dimethylxanthine
(LSF)) from PTX. The yeast used for the microbio-
logical reduction was employed under non-ferment-
ing conditions. In Table 1 a summary of the results
obtained using aqueous and organic media is given.
PTX was reduced by bakerís yeast (Saccharomyces
cerevisiae: strains ñ Líhirondelle and Asmussen) in a
water medium according to Prelogís rule (21) to give
the (S)-alcohol in good optical purities, ee 94% for
Asmussen and 64 % for Líhirondelle. Long-chain
ketones such as n-propyl-n-butyl ketone and several
bulky phenol ketones are not accepted. Only one
long alkyl chain is tolerated, as long as the other
substituent is the methyl group (22, 23). However,
LSF corresponds to the (R)-alcohols and therefore
for the following experiments some strains of wine
yeast were used as a biocatalyst. Bioreductions were
performed in water and organic solvents. Table 1
shows that in numerous cases such reductions can be
carried out quite successfully. PTX was reduced in
the presence of wine yeast in an aqueous medium
according to anti- Prelogís rule to give a similar (R)-
alcohol to that obtained in reduction with LKADH
(alcohol dehydrogenase from Lactobacillus kefiri)
(24, 25). The biotransformation of PTX with wine
yeasts in water produced LSF with different enan-
tiomeric excesses (ee from 37 % for KKP13 to 98 %
for KKPU) and different yields (from 48 % for
KKP82 to 95 % for KKPU). The biotransformation
process with KKPU was characterised by a high
enantioselectivity (ee = 98%) for the R isomer and a
high yield (95%). The KKPU strain was proved to
have the best LSF formation activity. However, in
organic media the yields of the reductions of PTX
into LSF were very small (from 1 to 23%). In ethyl
acetate all wine strains prefered to form an (S) iso-
mer, whereas in the toluene strains KKP82 and
KKP295 (R) isomers were formed. Drastic solvent
dependent ee changes were found for the reduction
of PTX by the KPP35 strain: 85 % ee in favor of the
(R) enantiomer in water and 98 % ee favoring (S)
enantiomer in toluene. Therefore, the reduction of
PTX with wine yeast can be performed in organic
solvents only in ethyl acetate and toluene, but with
low yield. When hexane was used for KKP82 and
KKPU the biotransformation of PTX was not
observed.
In summary, these results demonstrate that the
reduction of PTX in the water medium with the
KKPU strain offers an alternative new and highly
selective method of LSF formation. 
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